Feb. 6, 2025 — Despite new medication, cystic fibrosis often leads to permanent lung damage. Researchers have discovered that the disease causes changes in the immune system early in life ...

There was associated interstitial ... with impaired lung function that may not be evident on spirometric testing alone. Marijuana may contribute to bullous lung disease, although further evidence ...

Antifibrotic agents may be successful in the future. This is generally a nonsteroid-responsive lesion and for disabling disease, lung transplantation can be a successful option. Constrictive ...

According to the latest diagnostic criteria released by the Centers for Disease Control and Prevention (CDC) in 2018, a definite diagnosis of CJD can only be determined through positive brain tissue ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...

Articles were deemed eligible if the following criteria was met: (1) randomized controlled trials (RCTs); (2) included adults (≥18 years) with refractory chronic cough (>8 weeks) or those with ...

nbt.nhs.uk Secondary pneumothorax (SSP) is associated with underlying lung disease, in distinction to PSP, although tuberculosis is no longer the commonest underlying lung disease in the developed ...

This Review summarizes our current understanding of the mechanisms of tau-mediated neurodegeneration in Alzheimer's disease and related ... different stages of the pathology.

Welcome to the Lancet Global Burden of Disease (GBD) Resource Centre, bringing together the most comprehensive data and analysis of worldwide trends in global health, published across the Lancet ...

Autoimmune diseases are a pathophysiological state wherein immune responses are directed against, and damage, the body's own tissues (autoimmunity). Common examples of autoimmune disease include ...

Division of Pulmonary and Critical Care Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109, USA Dr J P Lynch III, Department of Internal Medicine, Division of Pulmonary and Critical ...

“Our work highlights GZMK as a promising therapeutic target to inhibit complement activation across multiple diseases. Unlike traditional therapies that broadly inhibit complement ...